XML 49 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Restatement of Previously Issued Unaudited Condensed Consolidated Financial Statements for the Three and Nine Months Ended September 30, 2018 - Schedule of Restatements (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Note receivable $ 300,000   $ 300,000  
Additional paid-in capital 16,376,192 $ 8,465,294 16,376,192 $ 8,465,294 8,465,294
Accumulated deficit (8,527,080) (1,661,847) (8,527,080) (1,661,847) $ (3,266,313)
Fair value of common stock issued in connection with the financing transaction 4,640,000 4,640,000  
Net loss (4,772,586) (203,390) (5,146,255) (714,550)  
Net loss attributable to common shareholders (4,853,200) (203,390) (5,260,767) (680,094)  
Comprehensive loss $ 4,928,052 $ 174,819 $ 5,368,906 $ 644,368  
Net loss per share, basic and diluted $ (0.09) $ (0.00) $ (0.10) $ (0.01)  
Issuance of notes receivable     $ (300,000)  
Net cash provided by (used in) investing activities     242,080 (130,584)  
Proceeds from shares issued for cash     3,463,705 984,864  
Net cash provided by financing activities     2,008,063 2,321,626  
Previously Reported [Member]          
Note receivable $ 6,300,000   6,300,000    
Additional paid-in capital 17,736,192 $ 8,807,968 17,736,192 8,807,968  
Accumulated deficit (3,887,080) (751,056) (3,887,080) (751,056)  
Fair value of common stock issued in connection with the financing transaction      
Net loss (132,586) (103,395) (506,255) 4,741  
Net loss attributable to common shareholders (213,200) (86,707) (620,767) 39,197  
Comprehensive loss $ (288,052) 94,392 $ (728,906) $ (16,472)  
Net loss per share, basic and diluted $ (0.00)   $ (0.01) $ (0.00)  
Issuance of notes receivable     $ (6,300,000)    
Net cash provided by (used in) investing activities     (5,757,920)    
Proceeds from shares issued for cash     9,463,705    
Net cash provided by financing activities     8,008,063    
Restatement Adjustment [Member]          
Note receivable $ (6,000,000)   (6,000,000)    
Additional paid-in capital (1,360,000) (342,674) (1,360,000) $ (342,674)  
Accumulated deficit (4,640,000) (910,791) (4,640,000) (910,791)  
Fair value of common stock issued in connection with the financing transaction 4,640,000   4,640,000    
Net loss (4,640,000) (99,995) (4,640,000) (719,291)  
Net loss attributable to common shareholders (4,640,000) (99,995) (4,640,000) (719,291)  
Comprehensive loss $ (4,640,000) $ 80,427 $ (4,640,000) $ 660,840  
Net loss per share, basic and diluted $ (0.09)   $ (0.09) $ (0.01)  
Issuance of notes receivable     $ 6,000,000    
Net cash provided by (used in) investing activities     6,000,000    
Proceeds from shares issued for cash     (6,000,000)    
Net cash provided by financing activities     $ (6,000,000)